Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmosa BiopharmROCO:6875 +0.14%11 Days Payable is 10.25 as of Dec. 2025, which is 42% below its 10-year median of 17.66. GuruFocus rates ROCO:6875 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 701 Biotechnology companies, Pharmosa Biopharm ranks worse than 93.58% on this metric.
The historical rank and industry rank for Pharmosa Biopharm's Days Payable or its related term are showing as below:
ROCO:6875'
s Days Payable Range Over the Past 10 Years
Min: 5.66 Med: 17.66 Max: 29.65
Current: 12.85
During the past 8 years, Pharmosa Biopharm's highest Days Payable was 29.65. The lowest was 5.66. And the median was 17.66.
ROCO:6875's Days Payable is ranked worse than 93.58% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs ROCO:6875: 12.85
Pharmosa Biopharm's Days Payable
declined
from Dec. 2024 (11.03) to Dec. 2025 (10.25).
It may suggest that Pharmosa Biopharmaccelerated paying its suppliers.
Pharmosa Biopharm Days Payable Related Terms
Pharmosa Biopharm Days Payable Historical Data
* Premium members only.
The historical data trend for Pharmosa Biopharm's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6875 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Pharmosa Biopharm's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmosa Biopharm Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmosa Biopharm's Days Payable distribution charts can be found below:
* The bar in red indicates where Pharmosa Biopharm's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Pharmosa Biopharm's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmosa Biopharm (ROCO:6875) has a Days Payable of 10.25 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pharmosa Biopharm and its competitors. This is 42% below median its historical median of 17.66. Over the past decade, Pharmosa Biopharm's Days Payable has ranged from 5.66 to 29.65. According to the industry distribution chart, Pharmosa Biopharm ranks #656 out of 701 companies in the Biotechnology industry, placing it in the top 93.6%.
Is Pharmosa Biopharm's Days Payable too high?
Pharmosa Biopharm's current Days Payable of 10.25 is 42% below median its 10-year median of 17.66. Over the past 10 years, this metric has ranged from a low of 5.66 to a high of 29.65. The Biotechnology industry median Days Payable is 112.84. Pharmosa Biopharm's value of 10.25 is 90.9% below this industry median. Based on the distribution chart, Pharmosa Biopharm ranks #656 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharmosa Biopharm has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Pharmosa Biopharm's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmosa Biopharm ranks #656 out of 701 companies for Days Payable. This places Pharmosa Biopharm in the lower half of its industry. The industry median Days Payable is 112.84. Pharmosa Biopharm's value of 10.25 is 90.9% below this benchmark. Historically, Pharmosa Biopharm's own Days Payable has ranged from 5.66 to 29.65 over the past decade. While the company's 10-year median is 17.66 vs. the industry median of 112.84, Pharmosa Biopharm has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmosa Biopharm's current Days Payable of 10.25 is 90.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pharmosa Biopharm and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmosa Biopharm's current Days Payable is 10.25, which is 42% below median its own 10-year median of 17.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmosa Biopharm stock overvalued right now?
Pharmosa Biopharm (ROCO:6875) has a current Days Payable of 10.25. The current Days Payable is 10.25, which is 42% below median its 10-year median of 17.66 and 90.9% below the Biotechnology industry median of 112.84. Pharmosa Biopharm's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pharmosa Biopharm (ROCO:6875), the current Days Payable is 10.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharmosa Biopharm Inc is a world-class biotechnology company. The Company's principal business activities comprise the development and commercialization of inventive biopharmaceutical drugs. Its product portfolio includes sustained-release dosage forms and drug-device combination products intended for home based therapies.
11GF Score
Get the complete analysis for ROCO:6875
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6875 has been successfully added to your 
